Co-occurrence of carbapenemase encoding genes in Acinetobacter baumannii, a dream or reality?

BACKGROUND: Acinetobacter baumannii is an important opportunistic pathogen that is rapidly evolving towards multidrug resistance and is responsible for life-threatening infections. Carbapenems are commonly used to treat A. baumannii infections but the emergence of carbapenemase encoding genes, such as blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, and blaNDM has been reported. Moreover, several studies have reported the co-occurrence of two distinct carbapenemases in some isolates. The aim of the present study is to demonstrate whether the phenomenon of co-occurrence of two distinct carbapenemase encoding genes in a single isolate still exists.
RESULTS: We studied six strains of A. baumannii including one harboring blaOXA-23-like and blaOXA-24-like genes and five with blaOXA-23-like and blaNDM genes. One colony of each strain was inoculated in sterile water and diluted ten-fold. Each dilution was cultivated on trypticase soy agar plates for 24 h at 37 °C and the isolated bacteria were analyzed. For two of the six tested strains, we identified two different populations of A. baumannii, each with a different carbapenemase, genes encoding aminoglycoside modifying enzymes, resistance phenotype, and clonal type. In addition, the two different populations had the same aspect on the agar plate.
CONCLUSIONS: Here, we demonstrate that A. baumannii infections could be linked to multiple clones harboring different carbapenemase encoding genes in the same sample. In addition, we describe an easy method of verifying the presence of co-occurrence of carbapenemase in one isolate.

Background

Acinetobacter baumannii is an important opportunistic Gram-negative bacteria pathogen that is rapidly evolving towards multidrug resistance. Worldwide, this bacterium is responsible for nosocomial infections and life-threatening infections [1]. The most common treatment is the use of carbapenems but extensive use of antimicrobial agents within hospitals has contributed to resistance against these antibiotics. The principal mechanism of resistance to carbapenems in A. baumannii is the production of OXA-type carbapenemases, such as OXA-23, OXA-24, and OXA-58 enzymes, and the new metallo-β-lactamase (MBL), New Delhi Metallo-β-lactamase 1 (NDM-1) [1].

The location of the carbapenemase genes is not fixed, since some studies have described blaOXA-23, blaOXA-24 and blaOXA-58 as chromosomal or plasmidic [2]. In epidemiologic studies, co-occurrences of carbapenemase genes, such as blaOXA-23-blaOXA-24, blaOXA-23-blaNDM, and blaOXA-58-blaNDM have been described [3-8]. In blaOXA-23 and blaNDM co-expressing Acinetobacter spp. strains, blaNDM can be acquired by plasmid [4, 9]. However, it remains unclear whether and how these co-existing carbapenemase genes are expressed and how they contribute to drug resistance. The aim of our study was to provide an alternative explanation for the coexistence of blaOXA and blaNDM genes in A. baumannii. For this purpose, we describe an easy method of determining whether the co-occurrence of carbapenemase genes in such bacteria was “real” or whether it is due to the existence of different bacterial clones harboring different genes in the same sample.

Results

Ten isolated colonies from the original diluted strain were analyzed and re-identified as A. baumannii using MALDI-TOF MS. Original strains 519, 598, 624, and 679 and all colonies tested were positive for both blaNDM and blaOXA-23 genes before and after the limit dilution (Table 1). We therefore considered them as “true” strains with the co-occurrence of different carbapenemase genes. Original strain 924 was positive for both blaNDM and blaOXA-23 genes. All 10 colonies obtained after the limit dilution were tested using real time PCR: six were positive only for the blaNDM gene while four were positive only for the blaOXA-23 gene. The original strain belonged to the sequence type ST2 as were the clones carrying the blaOXA-23 gene, whereas the clones harboring the blaNDM gene belonged to ST25 (Table 1).

Table 1

Analysis of the original A. baumannii strains and their clones

Strain	Date of isolation (month/ year)	Sample/Ward	Carbapenemase genes	Aminoglycoside genes	ST	CTX	CAZ	TIM	TPZ	ATM	IPM	CN	TOB	AK	CIP	SXT	DO	CT
						(μg/mL)
519 (n = 10)	03/2013	NA/ Intensive Care Unit	blaOXA-23- blaNDM-1	/	25	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 32)	R(32)	S(0.5)
598 (n = 10)	03/2013	NA/ Burns	blaOXA-23- blaNDM-1	/	25	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 32)	R(32)	S(0.5)
624 (n = 10)	03/2013	NA/ Intensive Care Unit	blaOXA-23- blaNDM-1	/	25	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 32)	R(32)	S(1)
679 (n = 10)	03/2013	NA/ Pediatric	blaOXA-23- blaNDM-1	/	25	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 256)	R(> 256)	R(32)	R(> 32)	R(> 32)	R(32)	S(0.5)
924 (n = 10)	05/2011	Pus/ Pus unit	blaOXA-23- blaNDM-1	aph(3′)-VI	2	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R (128)	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(> 32)	R(> 32)	R(> 256)	S(1)
924-A (n = 4)			bla OXA-23	aph(3′)-VI	2	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(16)	R(> 32)	S(0.093)	S(2)	R(> 256)	R(> 32)	R(> 32)	R(> 256)	S(0.5)
924-B (n = 6)			bla NDM-1	/	25	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(128)	R(> 32)	R(> 256)	R(> 256)	R(16)	R(> 32)	R(> 32)	R(24)	S(1)
AH35 (n = 10)	05/2011	Urine/ Intensive Care Unit	blaOXA-23- blaOXA-24	aph(3′)-VI, aac(3)-Ia, ant(2″)-I	2	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(> 256)	R(> 32)	R(8)	R(> 256)	R(24)	R(> 32)	R(> 32)	R(> 256)	S(0.5)
AH35-A (n = 6)			bla OXA-23	aph(3′)-VI, ant(2″)-I	2	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(> 256)	R(> 32)	S(0.064)	S(1)	R(16)	R(> 32)	R(> 32)	R(> 256)	S(0.5)
AH35-B (n = 4)			bla OXA-24	aac(3)-Ia	2	R(> 32)	R(> 256)	R(> 256)	R(> 256)	R(128)	R(> 32)	R(8)	R(> 256)	R(24)	R(> 32)	R(> 32)	R(> 256)	S(0.5)

CTX cefotaxime, CAZ ceftazidime, TIM ticarcillin + clavulanic acid, TPZ piperacillin + tazobactam, ATM aztreonam, IPM imipenem,

CN gentamycin, TOB tobramycin, AK amikacin, CIP ciprofloxacin, SXT trimethoprim-sulfamethoxazole, DO doxycycline, CT colistin, NA, not available, R resistant, S sensitive, ST sequence type

Original strain AH35 was positive for both the blaOXA-23 and blaOXA-24 genes. Of the 10 colonies which were obtained after the limit dilution, six were positive only for the blaOXA-23 gene while four were positive only for the blaOXA-24 gene. All strains (the original strain and the clones obtained after dilution) belonged to ST2 (Table 1). For the original strain AH35, resistance to aminoglycosides was due to the production of aminoglycoside-modifying enzymes (AMEs) aph(3′)-VI, ant(2″)-I and aac(3)-Ia. The clone (AH35-A) which was susceptible to gentamycin and tobramycin harbored the blaOXA-23, aph(3′)-VI and ant(2″)-I genes whereas the clone (AH35-B) which was resistant to these antibiotics carried the blaOXA-24 and aac(3)-Ia genes. The original strain 924 was positive for the presence of the aph(3′)-VI gene. The clone (924-A) which was resistant to amikacin harbored the blaOXA-23 and aph(3′)-VI genes; while no AME genes were found in the clone (924-B) carrying the blaNDM gene and resistant to amikacin with relatively low MIC. Original strains AH35 and 924 were chimeras of their two clones. The results of the antibiotic susceptibility testing (AST) of the obtained clones after the limit dilution revealed two different resistance phenotypes according to the aminoglycosides presented in the different clones (Table 1). After sub-culturing the two original strains (924 and AH35) in the same conditions and the same TSA medium (Fig. 1), we observed no phenotypic differences in terms of size, form or color.

Fig. 1

a Isolation of original strain AH35 blaOXA-23 and blaOXA-24 on TSA medium and isolation of clones. AH35A; blaOXA-23 on the left, AH35B; blaOXA-24 on the right. b Isolation of original strain 924 blaNDM and blaOXA-23 on TSA medium and isolation of clones 924A; blaOXA-23 on the left, 924B and blaNDM on the right

Discussion

Since A. baumannii is able to remodel its genome, antibiotic use and the host environment might impose selective forces that drive its rapid adaptive evolution. Microscale genome modification has been revealed through the analysis of single nucleotide polymorphisms (SNPs) between A. baumannii strains isolated from the same patient. This modification can lead the emergence of resistance and to different sequence typing by modifying a single allele [10]. However, this explanation cannot be applied to our case, because ST2 and ST25 have only two common alleles. Mutations in five alleles would be a substantial evolution. Moreover, this cannot be an evolution of a clone because the presence of different carbapenemase-encoding genes was also observed.

Another phenomenon, referred to as small colony variants (SCVs), mostly described in Staphylococcus aureus, was also identified from one sample with different susceptibility to antibiotics from the parent strain [11]. SCVs can cause latent and recurrent infections and have been observed in many genera of bacteria, including Gram-negative bacteria such as Pseudomonas aeruginosa [12]. In our case, the populations are morphologically identical and do not have the aspect of small colony variants.

The presence of different populations of a same species in the same sample had been already described in S. aureus [13]. Similarly to our study, different clones with different resistance phenotypes, such as methicillin-susceptible and methicillin-resistant S. aureus strains could be isolated from the same sample by increasing the number of colonies tested for each sample [14].

BlaOXA-23, blaOXA-24 and blaNDM can be located either on the chromosome or plasmid. For this reason, we tend to believe that co-occurrence with other resistance genes is due to the presence of different genes in the same strain. However, another explanation could be the presence of a polyclonal population of A. baumannii from the same sample. These populations are morphologically undetectable with the naked eye. Although the number of strains studied was limited, our work represents the proof of concept that co-occurrence of carbapenemases in A. baumannii could be due to multiple clones.

Conclusion

In this work, we demonstrated that from one sample and from an original “chimera” strain with two carbapenemase genes which were highly resistant to antibiotics, we were able to isolate two less resistant strains with only one gene encoding for carbapenems resistance. The presence of different clonal types and different genes encoding aminoglycoside modifying enzymes in each clone is also evidence of polyclonal coexistence in a single sample.

Another option, in similar case to this current study, is the coexistence in a single sample of different clones harboring one carbapenemase encoding gene as well as different resistance genes. In addition, this study has strong implications for clinical practice. The use of only one colony from one sample to conduct AST may omit another population which may be more resistant.

Methods

Six A. baumannii strains (924, 519, 598, 624, and 679) isolated from two Algerian hospitals were studied; five A. baumannii co-expressed blaOXA-23 and blaNDM genes recovered from a hospital in Algiers, and one A. baumannii (AH35) co-expressed blaOXA-23 and blaNDM gene isolated from a urine sample in an intensive care unit in a hospital in Setif (Table 1). These clinical isolates were taken for the purpose of this study. Identification was confirmed using matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF) (Microflex, Brüker Daltonics, Bremen, Germany) [15].

For each strain, one colony was inoculated in sterile water and diluted ten-fold to isolate a single clone. Each dilution was cultivated on Trypticase Soy Agar (TSA) plates for 24 h at 37 °C and isolated bacterial were analyzed. Antibiotic susceptibility was determined by minimum inhibitory concentrations (MICs) using broth microdilution method (Biocentric) for colistin and using the E-test method (bioMérieux) for others antibiotics tested in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Real time PCR was performed to verify the presence of the blaOXA-23, blaOXA-24 and blaNDM genes [16, 17]. Standard PCR amplification was carried out using primers for amplification of the aph(3′)-VI, ant(2″)-I, aac(3)-Ia, aac(6′)-Ib and armA genes [18]. Clonal types of the isolates were determined using multilocus sequence typing (MLST) in line with the Pasteur schemes (https://pubmlst.org/abaumannii/). Each stage of the materials and methods section is summarized in Fig. 2.

Fig. 2

Example of the study of the strain 924